<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03049852</url>
  </required_header>
  <id_info>
    <org_study_id>CBT-CS101</org_study_id>
    <nct_id>NCT03049852</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium</brief_title>
  <acronym>Pterygium</acronym>
  <official_title>A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cloudbreak Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cloudbreak Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24)

      Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup
      (n=51)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24)

      Objectives are to evaluate ocular safety and tolerability by biomicroscopy, ophthalmoscopy,
      intraocular pressure and visual acuity, and to assess general safety by physical exams, vital
      signs, clinical laboratory tests and adverse events reporting and to evaluate systemic
      CBT-001 exposure by Cmax, Tmax and an estimation of the area under the curve (AUC).

      Three dose cohorts will be planned with a dose ascending strategy to guide dose
      concentrations (n=8 per Cohort x 3 cohorts = 24). Primary pterygium patients will be selected
      in this phase because the main goal is to assess the safety and tolerability of CBT-001 and
      primary pterygium patients are much easier to recruit. The ~8 primary pterygium patients from
      each Cohort will be administered a single ocular drug dose at Day 1 in the eye with primary
      pterygium; the unaffected eye will be dosed with vehicle. Examinations will be performed at
      both screening day (Day 0) and Day 1. Blood samples at pre-dose, 0.25, 0.5, 1, 2, 4 and 8
      hours post dose will be taken at Day 1 to assess systemic pharmacokinetics (PK). The data
      will be reviewed by Data Review Committee (DRC) to determine whether to initiate enrollment
      for the next Cohort.

      Cohort 1 will begin at the lowest CBT-001 concentration of 0.02%, followed by an increasing
      dose to 0.05% for Cohort 2 and then to 0.2% for Cohort 3. If no safety issues are found at
      all doses, the highest dose of 0.2% will be used for the next phase study.

      Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup
      (n=51)

      Objectives are to evaluate ocular and systemic safety of CBT-001 in primary or recurrent
      patients that have moderate to severe pterygium vascularity and to assess whether CBT-001 is
      efficacious in reducing pterygium vascularity and pterygium lesion growth. The dosing will be
      4 weeks. The followup period will be 5 months.

      Study Population Characteristics: Approximately 50 (30 primary pterygium and 20 recurrent)
      patients will be enrolled at up to 3 centers to have an estimated 40 patients complete the
      study based on an anticipated dropout rate of 20%. Although we have no evidence to suggest
      attrition due to Adverse Effects (AEs), the dropout rate is most conservative based on
      industry experience in comparable clinical studies. Patients will be randomized in a 1:1
      treatment allocation to receive either CBT-001 0.2% or Vehicle.

      Dosage/Dose regimen: One drop of the assigned study medication will be administered in the
      study eye TID for 4 weeks. The study eye is defined as the qualified eye (i.e., the eye
      meeting the inclusion criterion for primary or recurrent pterygium). If both eyes are
      qualified, then the eye with the more severe vascularity grade on the Pterygium Hyperemia
      Grading Scale at the baseline (Day 1) visit will be the study eye. If both eyes meet the
      criterion and have the same severity, the right eye will be the study eye. Patients with
      bilateral pterygium will administer study medication only in the study eye. The fellow eyes
      in all study subjects will be untreated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2017</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pterygium Vascularity Change Assessed Using the Pterygium Hyperemia Grading Scale</measure>
    <time_frame>Change from baseline at 4 weeks</time_frame>
    <description>The primary efficacy variable is the change from baseline (Day 1) in severity grade of pterygium vascularity at Week 4. Pterygium vascularity intensity is based on color coordinates as measured by digital image analysis of pterygium photographs. The quantitative analysis of photographs using a 5-point Pterygium Hyperemia Grading Scale (0 = absent, 1 = trace, 2 = mild, 3 = moderate, 4 = severe) will be conducted at an independent image reading center.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular and General Safety and Tolerability</measure>
    <time_frame>One day</time_frame>
    <description>The ocular safety and tolerability are measured by biomicroscopy, ophthalmoscopy, intraocular pressure and visual acuity, and to assess general safety by physical exams, vital signs, clinical laboratory tests and adverse events reporting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal Pterygium Lesion Length Change From Baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>The Corneal Pterygium Lesion Length is measured from digital images of the eye by an independent image reading center.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Pterygium</condition>
  <arm_group>
    <arm_group_label>CBT-001 Ophthalmic Solution Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop in the study administered one time only for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop in the study administered three times daily (TID) for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBT-001 Ophthalmic Solution Multidose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop in the study administered three times daily (TID) for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBT-001 single dose</intervention_name>
    <description>One drop in the study administered one time</description>
    <arm_group_label>CBT-001 Ophthalmic Solution Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>One drop in the study administered three times daily (TID) for 4 weeks</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBT-001 Multi-dose</intervention_name>
    <description>One drop in the study administered three times daily (TID) for 4 weeks</description>
    <arm_group_label>CBT-001 Ophthalmic Solution Multidose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary pterygium with moderate vascularity (Pterygium Hyperemia Grading Scale â‰¥ 3)

        Exclusion Criteria:

          -  Active ocular disease, corneal abnormalities other than pterygium, active ocular
             infection, or any ocular pathology unrelated to pterygium in either eye that could
             affect the assessment of the pterygium

          -  History of ocular herpes disease in either eye

          -  Any ocular surgical procedure within the last 3 months

          -  Female patients who are pregnant, nursing, or planning a pregnancy during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Hovanesian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harvard Eye Associates</name>
      <address>
        <city>Laguna Beach</city>
        <state>California</state>
        <zip>92651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <results_first_submitted>January 28, 2020</results_first_submitted>
  <results_first_submitted_qc>January 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2020</results_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT03049852/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CBT-001 Ophthalmic Solution Single Dose</title>
          <description>CBT-001 Ophthalmic Solution Single dose in one day</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Multi-dose</title>
          <description>One drop in the study administered three times daily (TID) for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>CBT-001 Ophthalmic Solution Multi-dose</title>
          <description>One drop in the study administered three times daily (TID) for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CBT-001 Ophthalmic Solution Single Dose</title>
          <description>One drop in the study administered one time
CBT-001: One drop in the study administered one time</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Multi-dose</title>
          <description>One drop in the study administered three times daily (TID) for 4 weeks
Vehicle: One drop in the study administered three times daily (TID) for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>CBT-001 Ophthalmic Solution Multi-dose</title>
          <description>One drop in the study administered three times daily (TID) for 4 weeks
CBT-001: One drop in the study administered three times daily (TID) for 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.8" spread="11.6"/>
                    <measurement group_id="B2" value="49.4" spread="10.7"/>
                    <measurement group_id="B3" value="52.0" spread="12.1"/>
                    <measurement group_id="B4" value="50.7" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pterygium Vascularity Change Assessed Using the Pterygium Hyperemia Grading Scale</title>
        <description>The primary efficacy variable is the change from baseline (Day 1) in severity grade of pterygium vascularity at Week 4. Pterygium vascularity intensity is based on color coordinates as measured by digital image analysis of pterygium photographs. The quantitative analysis of photographs using a 5-point Pterygium Hyperemia Grading Scale (0 = absent, 1 = trace, 2 = mild, 3 = moderate, 4 = severe) will be conducted at an independent image reading center.</description>
        <time_frame>Change from baseline at 4 weeks</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Multi-dose</title>
            <description>One drop in the study administered three times daily (TID)
Vehicle: One drop in the study administered three times daily (TID) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>CBT-001 Ophthalmic Solution Multi-dose</title>
            <description>One drop in the study administered three times daily (TID)
CBT-001: One drop in the study administered three times daily (TID) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pterygium Vascularity Change Assessed Using the Pterygium Hyperemia Grading Scale</title>
          <description>The primary efficacy variable is the change from baseline (Day 1) in severity grade of pterygium vascularity at Week 4. Pterygium vascularity intensity is based on color coordinates as measured by digital image analysis of pterygium photographs. The quantitative analysis of photographs using a 5-point Pterygium Hyperemia Grading Scale (0 = absent, 1 = trace, 2 = mild, 3 = moderate, 4 = severe) will be conducted at an independent image reading center.</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>grade</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.5"/>
                    <measurement group_id="O2" value="-0.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular and General Safety and Tolerability</title>
        <description>The ocular safety and tolerability are measured by biomicroscopy, ophthalmoscopy, intraocular pressure and visual acuity, and to assess general safety by physical exams, vital signs, clinical laboratory tests and adverse events reporting</description>
        <time_frame>One day</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>CBT-001 Ophthalmic Solution Single Dose</title>
            <description>One drop in the study administered one time
One drop in the study administered one time in one day</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular and General Safety and Tolerability</title>
          <description>The ocular safety and tolerability are measured by biomicroscopy, ophthalmoscopy, intraocular pressure and visual acuity, and to assess general safety by physical exams, vital signs, clinical laboratory tests and adverse events reporting</description>
          <population>mITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild eye irritation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild foreign body sensation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Pterygium Lesion Length Change From Baseline</title>
        <description>The Corneal Pterygium Lesion Length is measured from digital images of the eye by an independent image reading center.</description>
        <time_frame>4 weeks</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>CBT-001 Ophthalmic Solution</title>
            <description>One drop in the study administered three times daily (TID)
CBT-001: One drop in the study administered three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>One drop in the study administered three times daily (TID)
Vehicle: One drop in the study administered three times daily (TID)</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Pterygium Lesion Length Change From Baseline</title>
          <description>The Corneal Pterygium Lesion Length is measured from digital images of the eye by an independent image reading center.</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.3"/>
                    <measurement group_id="O2" value="0.16" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.27</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CBT-001 Ophthalmic Solution Single Dose</title>
          <description>One drop in the study administered one time
One drop in the study administered one time in one day</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Multi-dose</title>
          <description>One drop in the study administered three times daily (TID)
Vehicle: One drop in the study administered three times daily (TID) for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>CBT-001 Ophthalmic Solution Multi-dose</title>
          <description>One drop in the study administered three times daily (TID)
CBT-001: One drop in the study administered three times daily (TID) for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <description>not treatment related</description>
                <counts group_id="E1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Discoloration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Foreign Body Sensation in Eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <description>Mild eye irritation</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza A infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr, Jinsong Ni</name_or_title>
      <organization>Cloudbreak Therapeutics, LLC</organization>
      <phone>9496789752</phone>
      <email>Ni-Jinsong@cloudbreaktherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

